Tusker Pharma India Profile
Key Indicators
- Authorised Capital ₹ 3.33 Cr
as on 09-12-2024
- Paid Up Capital ₹ 2.51 Cr
as on 09-12-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 10.36 Cr
as on 09-12-2024
- Revenue 261.41%
(FY 2019)
- Profit -42.28%
(FY 2019)
- Ebitda 79.30%
(FY 2019)
- Net Worth 5.10%
(FY 2019)
- Total Assets 300.27%
(FY 2019)
About Tusker Pharma India
The Corporate was formerly known as Tusker Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 3.33 Cr and a paid-up capital of Rs 2.51 Cr.
The company currently has active open charges totaling ₹10.36 Cr.
Kommera Harish and Chintalapati Nikhil serve as directors at the Company.
- CIN/LLPIN
U24100TG2015PTC100140
- Company No.
100140
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Aug 2015
- Date of AGM
12 Aug 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Tusker Pharma India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kommera Harish  | Director | 10-Aug-2015 | Current |
| Chintalapati Nikhil | Director | 10-Aug-2015 | Current |
Financial Performance and Corporate Structure Insights of Tusker Pharma India.
Tusker Pharma India Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 261.41% increase. The company also saw a substantial fall in profitability, with a 42.28% decrease in profit. The company's net worth moved up by a moderate rise of 5.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Tusker Pharma India?
In 2019, Tusker Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aceso Research Labs LlpActive 3 years 7 monthsKommera Harish and Chintalapati Nikhil are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 26 Nov 2020 | ₹3.57 M | Open |
Others Creation Date: 01 Jan 2018 | ₹10.00 Cr | Open |
How Many Employees Work at Tusker Pharma India?
Unlock and access historical data on people associated with Tusker Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Tusker Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Tusker Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
